The policy change on naloxone and its brand name, Narcan, will affect Independence members with pharmacy benefits. It is effective March 1 for those with fully insured business plans and April 1 for self-funded businesses. Policyholders who’ve met their deductible won’t have a copay at the pharmacy when filling their prescription.
“By removing a financial barrier to accessing naloxone, we can make the drug more readily available and hopefully save more lives,” said Richard Snyder, MD, CMO for Independence Blue Cross. “Our hope is that anyone struggling with opioid addiction can get appropriate treatment, but they have to be alive to take that step.”
Independence Blue Cross also has a five-day limit on initial low-dose opioid prescriptions.
More articles on payer issues:
Anthem: It’s not medically necessary for anesthesiologists to assist most cataract surgeries
HHS proposes executive order loosening regulations on short-term plans
New Mexico denies allegations of bias in awarding Medicaid contracts: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.